

GeNeuro publishes the English version of its 2016 Reference Document

Geneva, Switzerland, 2 May 2017 - GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis, publishes the English version of its 2016 Reference Document, which has been filed on April 28, 2017, with the “Autorité des Marchés Financiers (AMF)”.

This document is available to the public free of charge, as provided for in applicable legislation, and may be viewed and downloaded on the Company's website www.geneuro.com

The 2016 Reference Document includes the annual financial report, the report of the Chairman of the Board of Directors on the conditions for preparing and organizing the Board's activities and the internal control procedures, the Management Report, the auditors' reports and information about fees paid to statutory auditors.

About GeNeuro

GeNeuro's mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases, such as multiple sclerosis, by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in France at sites in Archamps, Haute-Savoie and in Lyon. It has 31 employees and rights to 16 patent families protecting its technology.

For more information, visit: www.geneuro.com

GeNeuro's contacts:

GeNeuro	NewCap (France)	Halsin Partners	LifeSci Advisors
Jesús Martin-Garcia Chairman and CEO +41 22 794 50 85 investors@geneuro.com	Julien Perez (investors) +33 1 44 71 98 52 Nicolas Merigeau (media) +33 1 44 71 94 98 geneuro@newcap.eu	Mike Sinclair (media) +44 20 7318 2955 msinclair@halsin.com	Chris Maggos (investors) +1 646 597 6970 +41 79 367 6254 chris@lifesciadvisors.com